ONCOGENE PHARMACEUTICALS

Name BGI Sentis Cancer + Discovery Panel (Tissue/ctDNA)
Description BGI’s Cancer+ Discovery Panel is designed to identify all classes of actionable genomic alterations, including SNP, CNV, InDels and Fusions, across a total of 508 cancer-related genes. Results are supported by in depth mutation analysis and pharmacogenomics information relating to 102 cancer therapeutics approved by the FDA or currently undergoing clinical trials.
Comprehensive Whole exome plus flanking intronic regions covered for all genes tested; one single assay that detects point mutations, deletions, insertions, duplications, rearrangements.
Recommended for Individuals having family history of cancer.
Gene Panel 74 genes in female test package 79 genes in male test package.
High Performance Sensitivity/Specificity > 99%.
TAT 20 Calendar Days.
Comprehensive Whole exome plus flanking intronic regions covered for all genes tested; one single assay that detects point mutations, deletions, insertions, duplications, rearrangements.
Recommended for Patients suspected of being at increased risk of HBOC.
Specimen Peripheral blood, DNA, Saliva.
High Performance Sensitivity/Specificity >99%.
TAT 20 Calendar Days.
TEST LIST GENE LIST
Sentis BRCA (2 genes) pane BRCA1, BRCA2
Sentis Hereditary Breast and Ovarian (26 genes) panel BRCA1, BRCA2, CHEK2, PALB2, BRIP1, TP53, PTEN, STK11, CDH1, ATM, BARD1, MLH1,NBN, MRE11A,MSH2, MSH6, MUTYH, PMS1,PMS2, RAD50, RAD51C, NF1, EPCAM, SMARCA4, HOXB13.
Name BGI Sentis Hereditary cancer screening
Description BGI’s Comprehensive Hereditary Cancer Panel provides information on 74-79 genes associated with 24 different types of hereditary cancer including some of the most commonly occurring cancers such as hereditary breast, ovarian, colorectal, prostate and stomach cancer. BGI detects different alterations including germline SNV, Indels and CNV.
Comprehensive Whole exome plus flanking intronic regions covered for all genes tested; one single assay that detects point mutations, deletions, insertions, duplications, rearrangements.
Recommended for Individuals having family history of cancer.
Gene Panel 74 genes in female test package 79 genes in male test package.
Specimen 5ml Peripheral blood.
TAT 20 Calendar Days.
TEST NIFTY-Non Invasive Fetal trisomy Test
PURPOSE Screening of fetus for genetic disorders
NIFTY test is suitable for, but not limited to, patients which exhibit any of these indications Maternal age 35 or older at delivery • Contradictions of invasive testing, and risk of miscarriage • History with prior pregnancy with chromosomal abnormality • Received IVF treatment • Previously suffered from Habitual abortion.
NIFTY test not suitable for patients with these indications: Maternal/Fetal/Placental Mosaicism • Mother/ father have chromosomal abnormality • Patient who have received blood transfusion within one year prior to testing • Patients who had transplant surgery • Patients who have stem cell therapy • Vanishing twin syndrome.
Specimen 5ml Maternal Blood.
Validation Clinically validated with proven >99% sensitivity based on a study of nearly 147,000 pregnancies.
Insurance Coverage Different insurance policies are available in case of confirmatory invasive testings.
TAT 7 days.
TOP